Background
Hybrid immunity, resulting from a combination of both natural SARS-CoV-2 infection and vaccination is common and thought to provide strong protection against infection and severe COVID-19. We evaluated nasopharyngeal (NP) SARS-CoV-2 viral loads, nucleocapsid (N) antigen levels, and the breadth of neutralizing antibodies (nAbs) in adults with hybrid immunity and those without prior infection but vaccinated during the acute phase of SARS-CoV-2 infection.
Methods
Within the VISION study, a prospective observational cohort study of adults in North Carolina, we compared nasopharyngeal (NP) viral loads and nucleocapsid (N) antigen levels, as well as the breadth of plasma neutralizing antibodies (nAbs) to SARS-CoV-2 variants between 59 individuals with hybrid immunity (characterized by the presence of N Abs and reported vaccination) and 122 individuals with only vaccine-mediated immunity following symptom onset of breakthrough SARS-CoV-2 infections between Oct, 2022 and Dec, 2023.
Results
Participants with hybrid immunity displayed substantially lower NP viral loads (mean 3.6 vs. 4.8 log10copies/mL) and N antigen levels, as assessed by antigen test negativity (86% vs. 46%), during breakthrough SARS-CoV-2 infections compared to those who were vaccinated only. Levels of nAbs against the original Wuhan and Delta strains were greater in those with the hybrid immunity compared to those who were vaccinated. However, the breadth of these nAbs remained limited in both groups, with low-level neutralization capacity against XBB1.5 and other more recent Omicron variants.
Conclusions
Compared to those who were vaccinated but had no detectable N Abs, participants with hybrid immunity had lower NP viral loads during SARS-CoV-2 breakthrough infection. The link between hybrid immunity and lower levels of NP viral load has important implications, including the potential to mitigate the severity of breakthrough infections and enhance the response to antiviral treatment. Additionally, lower viral loads, as well as the presence of pre-existing anti-N Abs in adults with hybrid immunity, may decrease the sensitivity of at-home antigen tests. Finally, our study indicates that the breadth of nAbs in individuals with hybrid immunity was limited against new variants, underscoring the importance of continuous monitoring and the need for adaptive vaccination strategies for the currently licensed spike protein-based vaccines as new variants emerge and/or immunity wanes.
Table or Figure
